PMID- 21632677
OWN - NLM
STAT- MEDLINE
DCOM- 20120315
LR  - 20151119
IS  - 1499-2752 (Electronic)
IS  - 0315-162X (Linking)
VI  - 38
IP  - 8
DP  - 2011 Aug
TI  - Serum MMP-3 level as a biomarker for monitoring and predicting response to 
      etanercept treatment in ankylosing spondylitis.
PG  - 1644-50
LID - 10.3899/jrheum.101128 [doi]
AB  - OBJECTIVE: To investigate whether level of serum matrix metalloproteinase-3 
      (MMP-3) can serve as a biomarker for monitoring and predicting response to 
      etanercept treatment in patients with ankylosing spondylitis (AS) in daily 
      clinical practice. METHODS: Ninety-two consecutive AS outpatients with active 
      disease who started etanercept treatment were included in this longitudinal 
      observational study. Clinical data were collected prospectively at baseline and 
      after 3 and 12 months of treatment. At the same timepoints, serum MMP-3 levels 
      were measured retrospectively by ELISA. RESULTS: Since baseline serum MMP-3 
      levels were significantly higher in male compared to female patients with AS, 
      data analysis was split for gender. Changes in serum MMP-3 levels after 
      etanercept treatment correlated positively with changes in clinical assessments 
      of disease activity and physical function in both male and female patients. 
      Receiver operating characteristic analysis in male patients showed that baseline 
      serum MMP-3 levels had poor accuracy (AUC < 0.7) to discriminate between 
      Assessments in Ankylosing Spondylitis 20 (ASAS20) or ASAS40 responders and 
      nonresponders after 3 or 12 months of treatment. The accuracy of change in serum 
      MMP-3 levels from baseline to 3 months in predicting response after 3 or 12 
      months of treatment was poor for ASAS40 (AUC < 0.7) or moderate for ASAS20 (AUC = 
      0.752 and 0.744, respectively), and was not superior to the accuracy of change in 
      the currently used objective biomarkers, erythrocyte sedimentation rate and 
      C-reactive protein. CONCLUSION: Although significant changes in serum MMP-3 
      levels were found after etanercept treatment, data analysis indicates that serum 
      MMP-3 levels are not very useful for monitoring and predicting response to 
      etanercept treatment in patients with AS in daily clinical practice.
FAU - Arends, Suzanne
AU  - Arends S
AD  - Department of Rheumatology and Clinical Immunology, University Medical Center 
      Groningen, University of Groningen, The Netherlands. S.Arends@reuma.umcg.nl
FAU - van der Veer, Eveline
AU  - van der Veer E
FAU - Groen, Henk
AU  - Groen H
FAU - Houtman, Pieternella M
AU  - Houtman PM
FAU - Jansen, Tim L T A
AU  - Jansen TL
FAU - Leijsma, Martha K
AU  - Leijsma MK
FAU - Bijzet, Johan
AU  - Bijzet J
FAU - Limburg, Pieter C
AU  - Limburg PC
FAU - Kallenberg, Cees G M
AU  - Kallenberg CG
FAU - Spoorenberg, Anneke
AU  - Spoorenberg A
FAU - Brouwer, Elisabeth
AU  - Brouwer E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110601
PL  - Canada
TA  - J Rheumatol
JT  - The Journal of rheumatology
JID - 7501984
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Biomarkers/*blood
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Longitudinal Studies
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Severity of Illness Index
MH  - Spondylitis, Ankylosing/*blood/*drug therapy/physiopathology
MH  - Treatment Outcome
EDAT- 2011/06/03 06:00
MHDA- 2012/03/16 06:00
CRDT- 2011/06/03 06:00
PHST- 2011/06/03 06:00 [entrez]
PHST- 2011/06/03 06:00 [pubmed]
PHST- 2012/03/16 06:00 [medline]
AID - jrheum.101128 [pii]
AID - 10.3899/jrheum.101128 [doi]
PST - ppublish
SO  - J Rheumatol. 2011 Aug;38(8):1644-50. doi: 10.3899/jrheum.101128. Epub 2011 Jun 1.